EA201890941A1 - Программируемые универсальные клеточные рецепторы и способы их применения - Google Patents

Программируемые универсальные клеточные рецепторы и способы их применения

Info

Publication number
EA201890941A1
EA201890941A1 EA201890941A EA201890941A EA201890941A1 EA 201890941 A1 EA201890941 A1 EA 201890941A1 EA 201890941 A EA201890941 A EA 201890941A EA 201890941 A EA201890941 A EA 201890941A EA 201890941 A1 EA201890941 A1 EA 201890941A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pucrs
cell receptors
methods
application
universal cell
Prior art date
Application number
EA201890941A
Other languages
English (en)
Russian (ru)
Inventor
Гуннар Йорг Флорис Кауфманн
Яньвэнь Фу
Янь-лян Чжан
Джеймс Т. Пэттерсон
Original Assignee
Сорренто Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сорренто Терапьютикс, Инк. filed Critical Сорренто Терапьютикс, Инк.
Publication of EA201890941A1 publication Critical patent/EA201890941A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201890941A 2015-10-23 2016-10-24 Программируемые универсальные клеточные рецепторы и способы их применения EA201890941A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562245978P 2015-10-23 2015-10-23
US201662382691P 2016-09-01 2016-09-01
PCT/US2016/058429 WO2017070654A1 (en) 2015-10-23 2016-10-24 Programmable universal cell receptors and methods of using the same

Publications (1)

Publication Number Publication Date
EA201890941A1 true EA201890941A1 (ru) 2018-11-30

Family

ID=58558187

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890941A EA201890941A1 (ru) 2015-10-23 2016-10-24 Программируемые универсальные клеточные рецепторы и способы их применения

Country Status (11)

Country Link
US (1) US20170112878A1 (enExample)
EP (1) EP3365016A4 (enExample)
JP (1) JP2018537076A (enExample)
KR (1) KR20180091820A (enExample)
CN (1) CN108883170A (enExample)
AU (1) AU2016341321A1 (enExample)
CA (1) CA3002774A1 (enExample)
EA (1) EA201890941A1 (enExample)
TW (1) TW201726914A (enExample)
UY (1) UY36961A (enExample)
WO (1) WO2017070654A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016341321A1 (en) * 2015-10-23 2018-06-07 Sorrento Therapeutics, Inc. Programmable universal cell receptors and methods of using the same
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2019010201A1 (en) * 2017-07-03 2019-01-10 Yale University REGULATED SMALL MOLECULE ADAPTER
KR20200076732A (ko) * 2017-11-03 2020-06-29 소렌토 쎄라퓨틱스, 인코포레이티드 Cd38-지시된 키메라 항원 수용체 작제물
WO2019173837A1 (en) * 2018-03-09 2019-09-12 Sorrento Therapeutics, Inc. Dimeric antigen receptors (dar)
AU2020369479A1 (en) * 2019-10-23 2022-05-26 University Of Florida Research Foundation, Incorporated Novel conjugation chemistry for catalytic antibody 38C2
US20230096410A1 (en) * 2020-03-06 2023-03-30 Sorrento Therapeutics, Inc. Innate Immunity Killer Cells Targeting PSMA Positive Tumor Cells
EP4225799A4 (en) * 2020-10-12 2024-11-20 Sorrento Therapeutics, Inc. CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS
EP4274852A4 (en) * 2021-01-11 2025-02-26 Eutilex Co., Ltd. BISPECIFIC EPITOP-BINDING PROTEIN WITH ANTI-4-1BB ANTIBODY AND PD-1 PROTEIN OR FRAGMENTS THEREOF AND USE THEREOF
CA3215938A1 (en) * 2021-04-23 2022-10-27 Henry Hongjun Ji Dimeric antigen receptors (dars) that bind gd2
WO2023154708A2 (en) * 2022-02-10 2023-08-17 The Scripps Research Institute Car-t therapies targeted via covalently bonded adapters

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268488B1 (en) * 1999-05-25 2001-07-31 Barbas, Iii Carlos F. Prodrug activation using catalytic antibodies
AU2004210088A1 (en) * 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring T cell response
CA2696627C (en) * 2007-08-17 2016-09-27 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP2483301A1 (en) * 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
EP2593142B8 (en) * 2010-07-12 2018-12-26 Pfizer Healthcare Ireland Multifunctional antibody conjugates
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN107188969B (zh) * 2011-04-08 2021-08-27 美国卫生和人力服务部 抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途
WO2013044225A1 (en) * 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
AU2016341321A1 (en) * 2015-10-23 2018-06-07 Sorrento Therapeutics, Inc. Programmable universal cell receptors and methods of using the same

Also Published As

Publication number Publication date
WO2017070654A8 (en) 2017-06-01
EP3365016A4 (en) 2019-07-17
KR20180091820A (ko) 2018-08-16
AU2016341321A1 (en) 2018-06-07
UY36961A (es) 2017-05-31
CA3002774A1 (en) 2017-04-27
WO2017070654A1 (en) 2017-04-27
EP3365016A1 (en) 2018-08-29
TW201726914A (zh) 2017-08-01
US20170112878A1 (en) 2017-04-27
JP2018537076A (ja) 2018-12-20
CN108883170A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
EA201890941A1 (ru) Программируемые универсальные клеточные рецепторы и способы их применения
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
CY1121934T1 (el) Αντισωματα anti-fcrn
PE20170704A1 (es) Agente terapeutico que induce citotoxicidad
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
EA201890169A1 (ru) Тау-связывающие антитела
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
CL2013001468A1 (es) Anticuerpo humano aislado que se une especificamente al receptor de glucagon humano o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o afeccion asociada con altos niveles de glucosa o cetona en sangre.
AR092662A1 (es) Anticuerpos anti-ddr1
CA2936543C (en) Immunomodulatory agents
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
EA201401065A1 (ru) Ang2-связывающие молекулы
EA201690503A1 (ru) Антитела
EA201400964A1 (ru) Cx3cr1-связывающие полипептиды
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
UA115906C2 (uk) Fc-ФРАГМЕНТ ІМУНОГЛОБУЛІНУ IgG4, ЯКИЙ МАЄ МОДИФІКОВАНУ ШАРНІРНУ ДІЛЯНКУ